🇺🇸 FDA
Patent

US 10071945

Nuclear receptor modulators and their use for the treatment and prevention of cancer

granted A61KA61K31/12A61K31/275

Quick answer

US patent 10071945 (Nuclear receptor modulators and their use for the treatment and prevention of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/12, A61K31/275, A61K45/06, A61P